LIXTE Identifies Key Enzyme For LB-100 Activation, Potential Biomarker For Cancer Treatment Response

LIXTE Biotechnology Holdings, Inc. has published new preclinical data highlighting the conversion of its lead clinical compound, LB-100, into its active form, endothall. The findings, published in BioXriv and the International Journal of Pharmaceutics, provide insights into activation mechanisms and potential patient selection biomarkers. These discoveries could help optimise patient selection and enhance the clinical impact of LB-100 in cancer treatment.

Bas van der Baan, LIXTE’s Chief Executive Officer, said, “Clinical trials with LB-100 currently are underway for treating ovarian and colorectal cancer. The latest pre-clinical data published in the International Journal of Pharmaceutics and BioXriv provide a better understanding of the underlying biological availability of LB-100 and endothall in patients. They will help us optimise patient selection for future clinical trials.”

The researchers at the Netherlands Cancer Institute discovered an enzyme that converts LB-100 into endothall and may serve as a biomarker to measure treatment effectiveness. BioPharmaWorks LLC showed through their studies that LB-100 has a slow hydrolysis rate at physiological levels, yet enzymatic activities enhance its conversion rates within the cells.